INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Drug Delivery & Environmental Sustainability
132
Issue No #132 Apr/May 2022
April 27th, 2022
Download PDF
Issue 132 - AprMay 2022
Inside the magazine
FORMULATION
Dr Steven Prestrelski
Xeris Pharmaceuticals
XERIJECT™: NON-AQUEOUS FORMULATIONS FOR SC INJECTION OF ULTRA-HIGH-CONCENTRATION BIOLOGICS
Steven Prestrelski introduces the XeriJect non-aqueous formulation technology that creates formulations with visco-elastic properties, opening the door to subcutaneous injection of difficult-to-formulate biologics, such as monoclonal antibodies, at very high concentrations.
EXPERT VIEW
Rob Udale
ARE GOVERNMENTS BANNING THE MOST ENVIRONMENTALLY FRIENDLY INHALER?
Rob Udale, Catriona Eldridge and Omar Shah assess the assertion that pMDIs are the most environmentally damaging of the available pulmonary drug delivery device archetypes, and explore some of the intricacies not accounted for in the public discourse surrounding pMDIs.
SUSTAINABILITY
Fran Pencliffe
Cambridge Design Partnership
SUSTAINABILITY: WHAT CAN THE HEALTHCARE SECTOR LEARN FROM CONSUMER DESIGN?
Fran Penrose considers the lessons the healthcare sector can draw from the fast-moving consumer sector when designing for sustainability and asks, “Can we go even further?”
SUSTAINABILITY
Christoffer Thomsen
Technolution
SUSTAINABILITY IN MEDTECH DEVELOPMENT: AN ITERATIVE APPROACH BASED ON ECODESIGN AND LIFE CYCLE SCREENINGS
Life Cycle Assessments are a valuable but time-consuming and, ultimately, retrospective method for assessing MedTech product sustainability. Christoffer Thomsen and Peter Werner Hansen dive into an iterative and data-driven approach to more sustainable MedTech development based on Ecodesign and Life Cycle Screenings.
SUSTAINABILITY
Rob Doorakkers
IGS GeboJagema
SMART SOLUTIONS TO REDUCE CARBON FOOTPRINT
Rob Doorakkers and Geert van Amstel discuss why the company decided to become carbon neutral, how it is working to make injection moulding more sustainable and how the organisation is minimising its impact on the environment.
SUSTAINABILITY
Dr Pierre Moulinie
Covestro LLC
DESIGNING DRUG DELIVERY DEVICES TO MEET EMERGING NEEDS AND SUSTAINABILITY GOALS
Pierre Moulinié, Isaac Platte and Lauren Zetts discuss how polycarbonate-based materials deliver value to emerging drug delivery devices.
SUSTAINABILITY
Nick Atkinson
Recipharm
HOW CAN THE PHARMA INDUSTRY PREPARE FOR NEW pMDI PROPELLANTS?
Nick Atkinson looks at the changes that are set to hit pressurised metered dose inhaler manufacturing as new propellants are introduced and how pharma companies can prepare for the switch.
EXPERT VIEW
Dr Jnanadeva Bhat
CAPSULES: CLASSIC DRUG DELIVERY FORM HOLDS POTENTIAL FOR SUSTAINABLE DELIVERY
Jnanadeva Bhat and Anita Solanki discuss the role that hard capsules are able to play in delivering a more sustainable pharmaceutical industry, both as an oral solid dosage form and in dry powder inhalers.
SUSTAINABILITY
Emil Fraenkel
Phillips Medisize
SUSTAINABILITY WITH THE ARIA AUTOINJECTOR: THE ROUTE TO FURTHER IMPROVEMENTS
Emil Fraenkel and Bjarne Sørensen investigate the route to further sustainability improvements for the Aria autoinjector. This article is a sequel to a benchmark study on the environmental impact of Aria presented by Phillips-Medisize in ONdrugDelivery Issue 126 (Oct/Nov 2021).
SUSTAINABILITY
Barbara Lead
SMC Ltd
SUSTAINABILITY CONSIDERATIONS FOR END-TO-END DRUG DELIVERY DEVICE SOLUTIONS
Barbara Lead outlines the sustainability efforts undertaken by SMC Group associated companies, including facilitating the transition from hospital to at-home treatment and investment in greener facilities.
Top